142 related articles for article (PubMed ID: 37126153)
1. Incidence, predictors, and outcomes of febrile neutropenia and neutropenia in patients with metastatic castrate-resistant prostate cancer receiving docetaxel.
Peltekian S; Sajwani S; Wang X; Kanji S
Support Care Cancer; 2023 May; 31(5):311. PubMed ID: 37126153
[TBL] [Abstract][Full Text] [Related]
2. Prevention of docetaxel-associated febrile neutropenia with primary granulocyte colony-stimulating factor in Chinese metastatic hormone-sensitive and castration-resistant prostate cancer patients.
Poon DMC; Chan K; Chan TW; Ng B; Siu S; Ng J; Johnson D; Lee KC;
Asia Pac J Clin Oncol; 2021 Apr; 17 Suppl 3():39-47. PubMed ID: 33860642
[TBL] [Abstract][Full Text] [Related]
3. Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer.
Hamid AA; Willson K; Vincent AD; Tamjid B; Lee M; Bergin A; Gan C; Campbell A; Stewart J; Pezaro C; Tran B; Weickhardt AJ
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e399-e404. PubMed ID: 29318740
[TBL] [Abstract][Full Text] [Related]
4. Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.
Yanagisawa T; Kimura T; Hata K; Narita S; Hatakeyama S; Enei Y; Atsuta M; Mori K; Obayashi K; Yoshihara K; Kondo Y; Oguchi T; Sadakane I; Habuchi T; Ohyama C; Shariat SF; Egawa S
Prostate; 2022 Oct; 82(14):1322-1330. PubMed ID: 35767376
[TBL] [Abstract][Full Text] [Related]
5. Febrile neutropenia and its associated hospitalization in breast cancer patients on docetaxel-containing regimen: A retrospective cohort study on duration of prophylactic GCSF administration.
Lee CF; Zhou K; Young WM; Wong CS; Ng TY; Lee SF; Leung K; Wong LKM; So KH; Tang W; Chong G; Chan SK; Yip YTE; Ma VYM; Yeung A; Chin CHY; Kwan MW; Tsang HT
Support Care Cancer; 2020 Aug; 28(8):3801-3812. PubMed ID: 31832822
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer.
Shiota M; Yokomizo A; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
Support Care Cancer; 2014 Dec; 22(12):3219-26. PubMed ID: 24996830
[TBL] [Abstract][Full Text] [Related]
7. Impact of granulocyte-colony stimulating factor on docetaxel-induced febrile neutropenia in patients with breast cancer.
Zekri J; Nawaz A; Rasool H; Ahmad I; Abdel Rahman H; Dada R; Abdelghany EM; Farag K; Ibrahim RB; Deibas MY; Kamel MK; Allithy A
J Oncol Pharm Pract; 2022 Dec; 28(8):1681-1686. PubMed ID: 34342555
[TBL] [Abstract][Full Text] [Related]
8. Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer.
Matsui A; Morise M; Tanaka I; Ozone S; Matsuzawa R; Koyama J; Hase T; Hashimoto N; Sato M; Hasegawa Y
Cancer Invest; 2020 Aug; 38(7):424-430. PubMed ID: 32643445
[TBL] [Abstract][Full Text] [Related]
9. Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort.
de Vries Schultink AHM; Crombag MBS; van Werkhoven E; Otten HM; Bergman AM; Schellens JHM; Huitema ADR; Beijnen JH
Cancer Med; 2019 Apr; 8(4):1406-1415. PubMed ID: 30802002
[TBL] [Abstract][Full Text] [Related]
10. Neutropenia Prevention in the Treatment of Post-docetaxel Metastatic, Castration-resistant Prostate Cancer With Cabazitaxel and Prednisone: A Multicenter, Open-label, Single-arm Phase IV Study.
Maluf FC; de Oliveira FAM; Liedke PER; Brust L; Inocêncio CG; Monteiro FSM; Smaletz O; Cubero DI
Clin Genitourin Cancer; 2021 Jun; 19(3):e171-e177. PubMed ID: 33610484
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer.
Nomura H; Hatogai K; Maki Y; Mochizuki N; Tanaka M; Saito S; Daiko H; Kojima T; Kawasaki T
Support Care Cancer; 2020 Apr; 28(4):1849-1854. PubMed ID: 31342165
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
[TBL] [Abstract][Full Text] [Related]
13. Risk Factors for Febrile Neutropenia Induced by Docetaxel Chemotherapy in Patients with Non-small Cell Lung Cancer.
Uchida M; Yamaguchi Y; Hosomi S; Ikesue H; Mori Y; Maegawa N; Takano A; Sato Y; Hosohata K; Muroi N; Tomii K; Hashida T; Nakamura T
Biol Pharm Bull; 2020 Aug; 43(8):1235-1240. PubMed ID: 32435013
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer.
Shigeta K; Kosaka T; Yazawa S; Yasumizu Y; Mizuno R; Nagata H; Shinoda K; Morita S; Miyajima A; Kikuchi E; Nakagawa K; Hasegawa S; Oya M
Int J Clin Oncol; 2015 Jun; 20(3):605-12. PubMed ID: 25196861
[TBL] [Abstract][Full Text] [Related]
15. Comparing the Incidence of Febrile Neutropenia Resulting in Hospital Admission Between the Branded Docetaxel and the Generic Formulations.
Faqeer NA; Mashni O; Dawoud R; Rumman A; Hanoun E; Nazer L
J Clin Pharmacol; 2017 Feb; 57(2):275-279. PubMed ID: 27479828
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of the Incidence of Febrile Neutropenia in Doxorubicin/Cyclophosphamide(AC)and Docetaxel/Cyclophosphamide(TC) Perioperative Chemotherapies for Primary Breast Cancer].
Nohara Y; Ono S; Tanaka M; Yoshinaga Y; Ito T; Yamashita S; Iwasaki A
Gan To Kagaku Ryoho; 2020 Nov; 47(11):1589-1591. PubMed ID: 33268733
[TBL] [Abstract][Full Text] [Related]
17. Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice.
Averin A; Silvia A; Lamerato L; Richert-Boe K; Kaur M; Sundaresan D; Shah N; Hatfield M; Lawrence T; Lyman GH; Weycker D
Support Care Cancer; 2021 Apr; 29(4):2179-2186. PubMed ID: 32880732
[TBL] [Abstract][Full Text] [Related]
18. Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment.
Assi H; Murray J; Boyle L; Rayson D
Support Care Cancer; 2014 Dec; 22(12):3227-34. PubMed ID: 24996828
[TBL] [Abstract][Full Text] [Related]
19. Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer.
Kimura Y; Sasada S; Emi A; Masumoto N; Kadoya T; Okada M
Support Care Cancer; 2021 Jul; 29(7):3507-3512. PubMed ID: 33146835
[TBL] [Abstract][Full Text] [Related]
20. Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.
Mager R; Savko O; Böhm K; Thomas A; Dotzauer R; Borgmann H; Jäger W; Thomas C; Haferkamp A; Höfner T; Tsaur I
Urol Oncol; 2019 Dec; 37(12):999-1005. PubMed ID: 31377168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
